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Abstract 
Decision–making by physicians on patients’ treatment has received increased research attention. 
Research on the effect of marketing strategies on prescription behaviour has tended to generate 
controversial results. While some researchers reported a strong influence, some found only moderate 
effects, while others find no influence at all. The main objective of this paper is to review the influence of 
the marketing strategies by pharmaceutical firms and contextual factors on physician attitude to drug 
prescription. The paper presents comprehensive information on pharmaceutical marketing efforts 
through exhaustive review of relevant literature, and identifies the moderating effects of contextual 
factors on physician prescribing decisions. It also presents a crucial conceptual model for explaining the 
theoretical linkages between marketing strategies of pharmaceutical firms, contextual factors and the 
decision of the physician regarding drug prescription.  
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Prescription drug marketing is unique. This 
uniqueness arises from the fact that the 
marketing strategies employed in the 
pharmaceutical industry differ from those used in 
other types of industries [1]. The decision maker 
is the physician, who decides which drug a 
patient will purchase, so the main focus of 
pharmaceutical firms is to influence the decision 
of the physician. Since prescription drugs 
constitute the major source of revenue for the 
pharmaceutical industry [2], marketing practices 
for prescription drugs have received the most 
attention from the industry [1].  The industry 
invests heavily in marketing efforts, using 20 – 40 
% of its revenue [3]. Most of these investments 
are directed to the physicians through medical 
representatives (MRs), and also through 
sampling and advertisements in medical journals 
[4]. According to industry data, visits by MRs 
represent the largest percentage of total 
promotion expenditure [5]. 
 
Aggregate prescription data suggest that 
promotion efforts increase drug prescription by 
physicians [6] and also stimulate sales of the 
drugs [7]. Thus traditionally, pharmaceutical firms 
spend more on promotion, and employ varieties 
of marketing strategies to maximize sales. 
Pharmaceutical industries claim that promotion 
efforts provide scientific and educational 
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information to physicians [8]. Indeed research 
findings suggest that many physicians see drug 
promotion as a useful and convenient source of 
information [7,9]. Other studies show that 
marketing tools have positive effects on the 
prescription behaviour of physicians [2,10]. 
However, there is still considerable debate on the 
effects of marketing strategies of the 
pharmaceutical firms on physician prescription 
attitude [11]. Some physicians deny being 
influenced by pharmaceutical promotional 
strategies [12,13]. Nonetheless, many of these 
physicians are willing to give significant amounts 
of time to promotional activities [14]. 
 
However serious concerns have been raised 
over the possibility that pharmaceutical firms 
might have undue influence on the prescription 
behaviour of physicians [15]. Indeed the World 
Health Organisation, WHO and some 
professional organizations are worried about the 
unethical promotion activities of pharmaceutical 
firms [16]. In particular, there is increased 
concern that a significant population of 
physicians might be prescribing a narrow range 
of heavily promoted, but needlessly expensive 
drugs, or exclusively branded products to the 
detriment of patient welfare [4]. Alongside the 
concern regarding the growth of pharmaceutical 
expenditure, there is also a concern regarding 
irrational or sometimes even harmful 
prescriptions [17], especially in developing 
countries [18]. Factors that affect decision to 
prescribe drugs are likely to be important in 
determining responses to over-prescription [19]. 
Marketing activities are crucial factors in this 
perspective [20]. The consequence of the above 
issues can result in loss of health and quality of 
life for patients and society. There is available 
evidence that pharmaceutical marketing efforts 
adversely influence prescription. Thus, 
governments, firms, and managers are beginning 
to pay attention to these factors that may affect 
physician drug decision–making [11]. 
 
Recently, Salmi et al [21] in a review that 
covered the period between 1990 and 2014, 
concluded that the marketing efforts of 
pharmaceutical companies exerted the greatest 
influence on the prescription of antibiotics by 
physicians. Kremer et al [10] conducted a meta-
analysis with the aim of formulating 
generalizations about the effectiveness of the 
pharmaceutical promotions, and concluded that 
these promotions are moderated by price. A 
2010 review reported no evidence of net 
improvements in prescription as a function of 
information (promotion tools) from 
pharmaceutical companies [8]. However these 
reviews narrowly focused on the relationship 
between marketing efforts and physician 
prescription in general.   
 
The objective of this review is to examine the 
relationship between prescription behavior of 
physicians, and marketing efforts such as drug 
information, drug brand, promotion mix and 
medical representatives directly provided by 
pharmaceutical companies. In addition, 
moderators of this relationship will be explored. 
 
Effects of pharmaceutical marketing 
strategies on physician prescription decision  
 
Review of literature has revealed significant 
influence of marketing promotion tools on 
physician prescribing behaviour [2,10]. The key 
role of these promotion techniques is to increase 
the number of prescriptions made [22]. Available 
evidence suggests that that marketing strategies 
have impact on physician prescribing behaviour 
either in the short – term [23] or in the long–term 
[24]. However it is not clear how these factors 
affect prescribing behaviour [25]. Even in the 
relatively developed research stream on 
marketing efforts and prescription behaviour, 
controversy has been raised recently [11]. While 
some authors have found significant effects of 
marketing tools on physician prescribing attitude 
[2,11,25,29], others have reported negative 
effects [30].  Moreover, the effect of promotion on 
prescription is not linear and shows diminishing 
returns [23] or no significant effect [15,31,32] or 
heterogeneity in physician responsiveness 
[10,33]. Although it is widely stated that 
marketing instruments increase prescription by 
physicians, this influence is thought to be, at 
most modest by some researchers [10,12,28,34]. 
 
The overall consensus is that marketing efforts 
frequently have a positive effect on physician 
prescribing [35]. Narayanan et al [6] and 
Venkataraman et al [11] have argued that 
marketing efforts may actually have both an 
informative role (e.g., reducing cognitive 
uncertainty) and a persuasive role (e.g., inducing 
positive effect). Both roles play a part in 
determining which drug to prescribe. However, 
the understanding of the link between marketing 
efforts and the prescription is far from complete. 
Moreover, the components of contextual 
circumstances under which this influence is 
exerted lack solid evidence. The study context, 
design and methodology used and main findings 
of studies on the effect of marketing efforts on 
prescribing are summarized in Table 1. 
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Table 1: Summary of previous research on pharmaceutical marketing strategies 
 
First author [ref no.] & 
country 
Methodology used Main findings 
Ladeira et al [2]  
Brazil 
A survey was conducted among 
physicians (n = 232).  
The results indicate that information 
on drug has the weakest effect, while 
the drug benefit/cost has moderate 
effect. Drug brand and its related 
advertising have the strongest effect.   
 
Hartono et al [30]. 
Indonesia 
Quantitative method involving 
physicians (n = 160)  
The main results showed that 
marketing mix negatively affect 
decision to prescribe drugs. 
 
 Zahrani [15]  
Saudi Arabia  
 
A cross-sectional study conducted by 
questionnaire for physicians (n = 
204)  
 Drug characteristics are the most 
important factors influencing physician 
prescription, while the least influence 
factor was MRs. There was no 
correlation between promotion tools 
and prescription. 
 
Ahmed et al [26]. Pakistan  
 
Survey of 100 physicians with 
randomly sampling.  
Marketing tools were positively related 
to prescribing behavior of physicians 
 
Parihar [28].   
India  
 
Survey data was collected from 150 
physicians. 
The findings indicate that (1) 
physicians are more concerned about 
brand name (2) promotion efforts are 
less effective on prescription (3) MRs 
have significant effects on prescribing 
behaviour.  
 
Saito et al [12].    
Japan 
Physicians both in office and hospital 
settings (n = 1411) completed the 
survey. 
The findings suggest that promotional 
activities have a modest impact on 
physician prescription. 
   
Parker et al [34].   
USA 
 
The questionnaire was distributed to 
363 staff physicians. 
The MRs have minimal impact on 
physician decision to prescribe drugs.  
 
Gonul et al [27].    
USA 
Experiment using a comprehensive 
panel of physicians’ data. 
The results indicate that promotions 
(detailing and samples) have a mostly 
informative effect on physician 
prescription.  
 
Klemenc-Ketis et al [31].   
Slovenia 
A cross-sectional survey including 
family physicians (n= 247). 
The assessment of MRs by family 
physicians does not have any 
substantial correlations with their 
prescription behavior. 
 
Al-Areefi et al [7]. Yemen Qualitative study:  An interview of 32 
physicians. 
Drug characteristics are the most 
important factors that influence 
prescribing decision, followed by 
marketing efforts of pharmaceutical 
companies. 
 
Ul-Haq et al [29]. Pakistan  Survey questionnaire responses from 
260 physicians. 
The results showed that promotional 
tools significantly affect the 
prescription of physicians, while 
branding is less affective. 
 
Campo et al [24].  
USA 
An interview was conducted for Both 
GPs and specialists in the US. 
The authors found that detailing may 
have a long lasting effect on 
prescription behavior. Detailing was 
found to increase prescription  
 
Rosenthal et al [32].  USA 
 
Panel data: examined monthly data 
from August 1996 to December 1999 
for five therapeutic classes of drugs. 
The main results show no significant 
effect of promotion on physician 
prescribing attitude. 
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Vancelik et al [14].   
Turkey 
A cross-sectional, survey was 
performed among 152 general 
physicians.  
Results showed  that promotional 
strategies influence physician 
prescribing behaviour 
   
Sagar et al [36].  
India 
Data was collected through 
structured questionnaire from 
physicians (n = 100). 
The results show that quality of a drug 
and the MRs are the most significant 
factors influencing prescription, while 
the promotional instruments have less 
influence.  
 
Kerak et al [9].  
Morocco  
 
Survey was conducted among 160 
physicians.  
The results show that overall, 
physicians regard as useful the 
medical information provided by MRs. 
 
Al-Hamdi et al [26]. Yemen  An interview with (n =30) physicians.  The current promotion activities of 
pharmaceutical firms are unethical. 
 
Venkataraman et al  [11] 
USA 
The study employed physician-level 
panel data. 
The results show that marketing 
efforts (detailing and meetings) affect 
physician prescribing. Drug attributes 
(effectiveness and side effects) 
moderate the relationship between 
marketing efforts and prescription.  
 
Kremer et al [10].  
Netherlands 
 
Systemic review of 58 studies. The results indicate that price 
moderates the effectiveness of 
promotion tactics on physician attitude 
to prescription.   
   
Janakiraman et al [33].  
USA 
Panel data examining 9672 
prescriptions written for depression 
by 108 physicians. 
The research indicates significant 
levels of persistence in drug choice. 
The non-persistent physicians are 
responsive to promotion (detailing and 
symposium meetings), whereas 
persistent physicians seem to be 
responsive only to symposium 
meetings. 
 
Information drug availability 
 
Information provided by pharmaceutical 
companies to targeted markets is the main factor 
affecting physician in selecting a company’s 
pharmaceutical products [37]. The decision of a 
physician to prescribe depends on currently 
available information about the pharmaceutical 
company and its drugs [38]. Physicians who 
prescribe drugs need and must acquire extensive 
information about the uses and limitations of new 
drugs [39].  In fact, physicians use the 
information about drugs to guide and justify their 
prescription choices [40]. There are various 
resources the physicians depends on when 
selecting one company’s product over another: 
these include leaflets, manuals issued by the 
MRs, internet, and medical journals [8]. MRs are 
considered to be one of the important sources of 
information for physicians in making their 
prescription decisions [38] especially in the 
developing countries where there may be as 
many as one MR for every five physicians [7].  
The internet provides easy information on drugs 
to physicians [40]. The spread of the media, in 
general, has provided physicians with numerous 
sources of information for decision making when 
prescribing drugs [1]. Another resource is 
advertising in the medical journals which 
communication is the form of information used by 
firms to persuade the readers of medical journals 
to prescribe the drug being advertised [24]. In 
this case, pharmaceutical firms need to 
understand what information sources physicians 
rely upon when they need to prescribe a drug 
[41]. 
 
Furthermore, previous research studies on drug 
information relied mainly on information 
prompted by prescribing drug advertising [14]. 
However, a few studies on the effect of drug 
information on prescription have been carried out 
[1], and are included in this review. Al-Areefi et al 
[7] and Theodorou et al [17] found that 
commercial sources of drug information influence 
physicians’ prescribing behaviour. Ladeira et al 
[2] found a positive effect of drug information on 
prescription drugs. 
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Many theories consider a brand to be a critical 
factor for maximizing company profits, creating 
competitive advantage, and facilitating 
communication between the pharmaceutical 
companies and consumers [42,43]. 
Pharmaceutical firms often have large marketing 
budgets and use mass promotion to create a 
brand image among customers [44]. This has 
been considered a major marketing phenomenon 
in the twenty-first century [2]. In the process of 
prescription decision making, brand can create 
sustainable points of differentiation among 
competing products and thus influence physician 
decision on choice of drug [42]. Physicians are 
actually the ultimate decision makers on the 
brand to be prescribed to their patients [29]. 
 
Much research has been done on whether or not 
branding plays a role in physician prescrption.  
Ladeira et al [2] found that drug brand had a 
significant positive effect on prescription. Parihar 
[28] found that brand is a prominent product 
feature influencing the physician prescription.  In 
contrast, Ul-Haq et al [29] showed that brand is 
does not have a strong influence on prescription. 
However, evidence from Yemen suggest that the 
branded drugs are prescribed very highly by 
physicians, which makes the role of the brand 
more evident [37]. 
 
Effectiveness of medical representatives 
(MRs) 
 
Pharmaceutical sales representatives remain the 
most important marketing instruments available 
to the industry [24].  Among all promotional 
interventions employed by the pharmaceutical 
industry directed at influencing prescribing, MRs 
are the strongest appreciated by physicians [14]. 
It is widely stated that MRs influence prescription 
[7,10,23,27]. However, the picture painted in the 
literature is not as clear as it may appear at first 
glance. Effects of MRs on prescribing behaviour 
can loosely be categorised into two categories: 
increased prescribing and mixed effects. 
 
Several authors find that MRs increase 
prescription at the physician level [17,27,45]. 
Strong evidence to support this notion stems 
from the fact that the pharmaceutical industry 
invests heavily in this promotional instrument. 
For example, $20.4 billion was spent on MRs 
visits in the US in 2004, representing 35.5 % of 
the total promotional expenditure [7]. Another 
estimate is that MRs visits cost about $3,300 
million and accounted for 75 % of the overall cost 
of promotion in 2008 [8]. Furthermore, using 
aggregate sales data, several authors also find 
that MRs increase physician prescriptions [6]. 
 
In the mixed effects category, several authors 
found that the effect of MRs is just modest [10]. 
Many studies that use quantitative data find a 
negligible positive effect of MRs on drug sales 
[15,34].  Also, some authors have found no 
significant effect of MRs on physician prescribing 
attitudes [31], while others have even found a 
negative effect [46]. In spite of some inconclusive 
results, in general, MRs serve two roles: 
information and persuasion [39]. Both roles play 
an important role in prescribing the drug.  
 
Promotion mix  
 
Pharmaceutical promotion mix (sampling, gifts, 
and sponsored medical education) play an 
important role in informing the physicians about 
differences between competing drugs available 
in the market [47,48]. Physician-oriented 
promotion increases the likelihood that 
physicians will prescribe the drugs [47]. There is 
significant empirical evidence that promotion 
instruments have a positive impact on 
prescription [10,14,26,36]. The recognition of the 
close interrelation of these two constructs has 
also affected managerial practice.  For example, 
many pharmaceutical companies spend billions 
of USD every year on promotion to persuade the 
physicians to change their prescribing decisions 
[3]. 
 
However, it is desirable that the impact of 
promotion on the physician is not always strong. 
This assumption is also supported by previous 
empirical findings that reveal a broad range of 
effect strengths ranging from strong [2,29] to 
weak [28], supporting the earlier articulated view 
that the effects of promotional instruments are 
heterogeneous [10]. Furthermore, recent studies 
found a significant relationship between 
promotion and prescription, although the effects 
were small [10,48,49], while others find no effect 
[15]. In the context of persuasion, pharmaceutical 
promotion may exert large persuasive influence 
on physician decision-making.  
  
Contextual factors as moderators 
 
Contexts are a set of circumstances or facts 
surrounding prescription events. These contexts 
are present at the time of decision 
making/prescription, and by modulating the level 
of uncertainty, may influencing physicians’ 
decisions [17]. Physician habit persistence [33], 
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drug attributes [11], and the cost-benefit ratio of a 
drug [2,17] are all contextual factors that have 
high influence on physician prescription attitudes, 
and modulates the interventions designed to 
create changes in prescription behaviour.  
 
This study posits these contextual factors are 
potential sources affect the responsiveness of 
physicians to prescription in response to 
marketing efforts of pharmaceutical firms. These 
factors are examined and discussed in the 
following sections. 
  
Moderating effects of drug characteristics 
 
Even though prior research has stated that drug 
characteristics (drug’s effectiveness and the 
side–effects) may moderate promotion effects 
[10], their role in conjunction with marketing 
efforts (such as drug brand, promotion mix, drug 
information and MRs effectiveness) on physician 
decision making remains unexplored. While a 
drug can be characterized along many 
dimensions, such as its approved interactions, 
collateral effects, kind of product category, and 
quality [2,26], this study will focus on all product 
characteristics. 
 
Drug attributes play a key role in evaluating 
prescription decision in both developing and 
developed countries. Ladeira et al [2] 
investigated the effect of drug attributes on 
prescription in Brazil, and concluded that 
characteristics positively affect prescription.  Al–
Areefi et al [7] found that Yemeni physicians are 
influenced most by drug characteristics. Further 
support is provided by another study [28], which 
reported that product merits are strongly affect 
physician prescription behavior in India.  
Theodorou et al [17] found that clinical 
effectiveness is the most important factor, 
reaching 94.9 and 93.3 % in Greece and Cyprus, 
respectively. Schumock et al [50] found that 
drugs attributes are considered highly influential 
by all participants in the USA. Therefore, there 
appears to be a consensus on drug attributes as 
a strong factor influencing physician prescription 
behavior.  
 
Venkataraman et al [11] stressed the significance 
of including drug characteristics in any study of 
the influence of drugs on the physician’s 
treatment decisions. In light of this, it is argued 
that when a firm promotes higher drug attributes, 
as compared to lower characteristics, the 
physician’s doubts about the drug are lowered 
due to stronger scientific evidence to back up the 
marketing efforts. 
Moderating effects of benefit–cost profile of 
drugs 
 
Product characteristics may not be enough to 
convince physicians to prescribe drugs. 
Enhancing the cost-benefit ratio of a drug is 
important in providing competitive advantages for 
the drug firm. According to the marketing 
literature, perceived value is the consequence of 
an overall assessment of perceived benefits and 
costs.   The cost– benefit ratio of a drug could be 
important at the time of the prescription [2]. Kim 
et al [1] suggest that the physicians should be 
well– informed on the cost– benefit ratio at the 
time of prescribing drugs. The physicians use the 
dimensions related to benefits and the cost of the 
drug to evaluate prescription drugs. In practice, 
the physician is responsible for making this 
assessment on behalf of the patient [2]. 
 
Literature review showed that physicians rate 
cost to be an important influence on prescribing 
behavior [51]. Whilst physicians emphasize 
clinical efficacy, they seem willing to take cost 
under certain conditions [2]. The benefits of the 
drug were found to be a distinct factor influencing 
prescription [52]. In developing countries, the 
consumption of drugs is largely linked to the 
purchasing power of the patient [2]. For example, 
study by Al–Areefi et al [7] found that the 
financial situation of patients and their ability to 
pay exert a powerful influence on prescription by 
Yemeni physicians. In this situation, it is 
unreasonable to expect the cost-benefit profile of 
a drug as not to influence physician prescribing 
behavior. 
 
The economic theory of utility perspective 
assumes that consumers are economically 
rational, so they will try to achieve the maximum 
utility with minimum resources such as cost, 
time, and risks [53]. In contrast, the means– end 
chain theory explains that personal values guide 
people’s evaluations of relevant the benefits of a 
product, and then these evaluations initiate goal– 
direct purchase behavior [54]. Hence, in the case 
of prescription when the physician’s perceived 
value is high, it has positive effect on the drug 
product. In other words, physicians are believed 
to choose certain drugs based on their superior 
value compared to competing products.  
 
The benefit– cost profile of a drug is not a static 
factor. Kremer et al [10] found that effectiveness 
of pharmaceutical promotion on physician 
prescribing behavior is moderated by price. This 
research suggests that the benefit–cost ratio of a 
drug may be a significant moderator of effect, 
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which is suggested to be a key driver of 
physician behavior in a seminal work by Ladeira 
et al [2]. Logically as in developing countries 
context, it will be harder for companies to 
persuade physicians to treat patients with an 
expensive drug, or drug of low benefits, 
compared to a drug with a high value. Thus, the 
total interaction effect of benefits–cost ratio and a 
firm’s marketing efforts is difficult to predict ex– 
ante, and hence is worthy of empirical 
investigation.  
 
Moderating effects of physician habit 
persistence 
 
Physician’s habit persistence in this research 
refers to choice of a drug made without cognitive 
involvement, and a choice known to influence 
physicians’ decisions when prescribing [55]. 
From an economic theory perspective, it may be 
argued that habit persistence is brand loyalty 
created by persuasive pharmaceutical 
promotions [38,39]. In practice, physicians, 
during clinical duties, may develop certain 
methods in which to practice administering the 
drugs. This established practice has been 
suggested to be subject to the persistence of the 
habit [33]. Thus, habit persistence may simply be 
driven by the economy of decision–making, it is 
necessary for the physician to form habits to 
reduce the burden of decision making related to 
the act of prescribing. 
 
The factor of habit persistence as a strong 
influence on physician prescribing is not 
surprising when considering the complexities of 
prescribing decision. Venkataraman & 
Stremersch [11] and Coscelli [56] found that 
there is substantial habit persistence in physician 
decision making. More importantly, Janakiraman 
et al [33] found habit persistence to be 
responsive to sampling and detailing. Therefore, 
it can reasonably be argued that physician–level 
habit persistence must be overcome for the 
marketing effort to have meaningful influence on 
physician prescribing behavior. Conversely, it 
can also be argued that physician – level habit 
persistence modulates any influence imparted by 
marketing efforts on physician prescribing 
decision. However, there no research works 
have attempted to address physician persistence 
as a moderator of the relationship between 





This paper offers several theoretical insights. 
First, although marketing efforts influencing 
physician prescribing decision have been widely 
studied, there is a fair amount of debate on its 
effects on prescription behaviour. This needs 
further investigation. The linkage between these 
constructs and evidence of how and under which 
circumstances (contexts) influence is exerted is 
lacking. Thus, the paper argues that contextual 
factors such as drug attribute, physician 
persistence habit, and benefit – cost ratio of a 
drug may tip the balance in this debate. This 
paper proposes a novel model of physician 
prescribing decision in a delineated model where 
eight underlying constructs are identified and 
combined. Under such a theoretical model, 
irrational prescribing phenomena could be 
investigated, especially in developing countries, 
with the aim of determining how marketing 
factors influence prescription attitudes. The 
proposed framework (Figure 1) is a robust 





    Figure 1:  Proposed research model 
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